<DOC>
	<DOCNO>NCT02530710</DOCNO>
	<brief_summary>Randomized , double-blind , placebo-controlled , dose-escalation study healthy male female volunteer . Subjects randomly assign 1 7 treatment cohort ( Cohorts 1 - 7 ) 8 subject , receive either Q203 placebo ( 6 active treatment : 2 placebo ) fast state . Dose escalation next cohort may consider least 6 8 subject , cohort , complete procedure none subject clinically significant adverse event ( AE ) follow , discretion PI drug-related serious adverse event ( SAEs ) occur . A food effect cohort enrol test administration Q203 feed state , 100 mg dose level ( dose level may change base PK analysis result ) . Subjects receive 100mg dose fast state return receive second dose , food . Subjects follow AEs , SAE pregnancy 30 day postdrug administration .</brief_summary>
	<brief_title>A Dose-Escalation Study Evaluate Safety , Tolerability Pharmacokinetics Single Doses Q203 Normal , Healthy , Male Female Volunteers</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , dose-escalation study healthy male female volunteer . Subjects randomly assign 1 7 treatment cohort ( Cohorts 1 - 7 ) 8 subject , receive either Q203 placebo fast state . Every attempt make include least 2 female cohort , least one assign receive Q203 . Dose escalation next cohort may consider least 6 8 subject , cohort , complete procedure none subject clinically significant adverse event ( AE ) follow , discretion PI drug-related SAEs occur . A food effect cohort enrol test administration Q203 feed state , 100 mg dose level ( dose level may change base PK analysis result ) . Subjects receive 100mg dose fast state return receive second dose , food . In cohort , eight subject proceed receive either Q203 placebo six two ratio ( six active treatment : 2 placebo ) . Every attempt make include least 2 female cohort , least one assign receive Q203 . Subjects follow AEs , SAE pregnancy 30 day postdrug administration .</detailed_description>
	<criteria>1 . Able understand sign inform consent form . 2 . Healthy adult male female nonchildbearing potential , age 18 55 year , inclusive time screen . 3 . Body mass index 18 32 kg/m2 , inclusive , weigh least 50 kg . 4 . Female subject must nonchildbearing potential ( postmenopause surgical sterilization ) . Postmenopausal status confirm folliclestimulating hormone ( FSH ) test screening . 5 . Male subject must agree use condom spermicide engage sexual intercourse study period 30 day study drug dosing , vasectomy least 6 month study start . 6 . Male subject must donate sperm study 30 day study drug dose . 7 . Able understand comply study requirement . 8 . Able swallow 8 tablet succession . 9 . Willing fast minimum 8 hour checkin . 10 . Agree donate blood , plasma , platelet blood component 1 month receive study drug . 11 . Willing abstain alcohol use 48 hour checkin end study . 12 . Willing forgo sunbathe prolonged exposure sunlight study period . 13 . Willing forgo strenuous exercise study period . 1 . Any known chronic systemic viral infection ( include positive serological test HIV , HBsAg HCAb indicate infection ) . 2 . History current active tuberculosis ( TB ) . 3 . Any systemic infection systemic illness , include persistent cough , respiratory , flulike symptom , previous 30 day screen . 4 . History histoplasmosis , coccidioidomycosis , similar opportunistic fungal infection . 5 . Vaccination previous 30 day screen . 6 . History , clinically significant evidence , bradycardia , syncope , ECG abnormality cardiovascular abnormality . 7 . Resting heart rate ( HR ) screen baseline ECG few 50 beat per minute ( bpm ) . 8 . History seizure . 9 . History drug ( include amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine , cannabinoids ) alcohol abuse addiction within past 2 year , male , consume 28 unit alcohol per week , female , consume 21 unit alcohol per week ( 1 unit alcohol equal 250 mL beer , 100 mL wine , 25 mL spirit ) . 10 . Any history abnormal pulmonary function ( e.g. , asthma related respiratory illness ) . 11 . Current recent ( within past 3 month ) use tobacco nicotinecontaining product positive result nicotine test screen checkin . 12 . Use prescription overthecounter ( OTC ) drug herbal product within 14 day dose . 13 . Use known drug metabolism enzymealtering drug ( inducer inhibitor ) supplement ( e.g. , St. John 's wort ) within 14 day dose consumption food beverage contain alcohol grapefruit within 48 hour dose . 14 . Use QTprolonging agent , include , limited , azithromycin , bepridil chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide dofetilide , domperidone , droperidol , erythromycin , Halofantrine , haloperidol , ibutilide , levomethadyl , lumefantrine , mefloquine , mesoridazine , methadone , moxifloxacin , pentamidine , pimozide , procainamide , quinidine , quinine , roxithromycin , sotalol , sparfloxacin , terfenadine , thioridazine , within 28 day dose end study . 15 . Any prior exposure Q203 participation another investigational drug study within previous 30 day screen . 16 . Any donation blood , plasma , platelet significant loss blood within 56 day dose . 17 . Laboratory result outside normal range , consider clinically significant PI designee . 18 . Hemoglobin concentration &lt; LLN . 19 . Any condition might interfere absorption study medication . 20 . History hypersensitivity idiosyncratic reaction product administer study . 21 . History unexplained syncope faint collection blood , i.e. , autonomic dysfunction . 22 . History hypotension , include orthostatic hypotension . 23 . Inability understand verbal and/or write English . 24 . Subjects glucose6phosphatedehydrogenase ( G6PD ) deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>